2seventy bio (TSVT) News Today → Biden FINISHED On June 13th? (From Paradigm Press) (Ad) Free TSVT Stock Alerts $4.77 +0.28 (+6.24%) (As of 04:31 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 1:14 AM | americanbankingnews.comQ2 2024 Earnings Forecast for 2seventy bio, Inc. Issued By Wedbush (NASDAQ:TSVT)May 12 at 3:57 AM | americanbankingnews.comCanaccord Genuity Group Cuts 2seventy bio (NASDAQ:TSVT) Price Target to $11.00May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for 2seventy bio on Strong Growth Prospects and Financial StabilityMay 9, 2024 | msn.com2seventy bio, Inc. (NASDAQ:TSVT) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finance.yahoo.com2seventy bio Inc (TSVT) Q1 2024 Earnings: Misses Revenue Estimates Amid Strategic RealignmentsMay 9, 2024 | uk.finance.yahoo.com2seventy bio Inc (TSVT) Q1 2024 Earnings Call Transcript Highlights: Strategic Shifts and ...May 8, 2024 | markets.businessinsider.comHere's what Wall Street expects from 2seventy bio's earningsMay 8, 2024 | investorplace.comTSVT Stock Earnings: 2seventy bio Meets EPS, Misses Revenue for Q1 2024May 8, 2024 | businesswire.com2seventy bio Reports First Quarter Financial Results and Recent Operational ProgressMay 4, 2024 | marketbeat.com2seventy bio (TSVT) Set to Announce Quarterly Earnings on Wednesday2seventy bio (NASDAQ:TSVT) will be releasing earnings before the market opens on Wednesday, May 8, Zacks reports.May 3, 2024 | finance.yahoo.com2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024May 3, 2024 | businesswire.com2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024April 17, 2024 | msn.com2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's WhyApril 13, 2024 | morningstar.com2seventy bio Inc Ordinary SharesApril 10, 2024 | investing.comCiti raises 2Seventy Bio stock target on FDA approvalApril 10, 2024 | marketbeat.comAnalysts Offer Predictions for 2seventy bio, Inc.'s Q1 2024 Earnings (NASDAQ:TSVT)2seventy bio, Inc. (NASDAQ:TSVT - Free Report) - Analysts at Leerink Partnrs issued their Q1 2024 EPS estimates for 2seventy bio in a report issued on Sunday, April 7th. Leerink Partnrs analyst D. Graybosch forecasts that the company will post earnings per share of ($0.49) for the quarter. LeerinApril 9, 2024 | marketbeat.comLeerink Partnrs Analysts Raise Earnings Estimates for 2seventy bio, Inc. (NASDAQ:TSVT)2seventy bio, Inc. (NASDAQ:TSVT - Free Report) - Investment analysts at Leerink Partnrs boosted their FY2028 EPS estimates for 2seventy bio in a report issued on Sunday, April 7th. Leerink Partnrs analyst D. Graybosch now expects that the company will earn $2.52 per share for the year, up from thApril 8, 2024 | markets.businessinsider.comPositive Outlook for 2seventy bio’s ABECMA: Buy Rating Affirmed Amidst Expansion and Competitive DynamicsApril 8, 2024 | marketbeat.com2seventy bio (NASDAQ:TSVT) Price Target Raised to $12.00Citigroup lifted their price objective on shares of 2seventy bio from $9.00 to $12.00 and gave the stock a "buy" rating in a research note on Monday.April 7, 2024 | markets.businessinsider.comBuy Rating and High Risk for 2seventy bio: FDA Approval and Market Expansion Fuel Optimistic OutlookApril 5, 2024 | msn.comBristol Myers Wins FDA Nod for AbecmaApril 5, 2024 | msn.comFDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary CancerApril 5, 2024 | seekingalpha.comBristol Myers, 2seventy bio's Abecma approved for earlier line multiple myelomaApril 5, 2024 | finance.yahoo.comU.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of TherapyApril 4, 2024 | marketbeat.com2seventy bio, Inc. (NASDAQ:TSVT) Receives Consensus Recommendation of "Hold" from BrokeragesShares of 2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) have been given an average rating of "Hold" by the eight brokerages that are currently covering the stock, Marketbeat reports. Five analysts have rated the stock with a hold rating and three have issued a buy rating on the company. TheMarch 26, 2024 | insidertrades.comInsider Buying: 2seventy bio, Inc. (NASDAQ:TSVT) Director Buys 300,000 Shares of StockMarch 25, 2024 | marketbeat.comInsider Buying: 2seventy bio, Inc. (NASDAQ:TSVT) Director Acquires 300,000 Shares of Stock2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) Director Casdin Capital, Llc acquired 300,000 shares of the stock in a transaction dated Thursday, March 21st. The stock was bought at an average cost of $4.90 per share, with a total value of $1,470,000.00. Following the completion of the purchase, the director now directly owns 1,482,623 shares in the company, valued at $7,264,852.70. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.March 20, 2024 | msn.com2seventy bio appoints Eli Casdin and Charles Newton to its board of directorsMarch 20, 2024 | businesswire.com2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of DirectorsMarch 20, 2024 | morningstar.comThinking about buying stock in 2Seventy Bio, Verb Technology, Exscientia, MicroCloud Hologram, or Akebia Therapeutics?March 18, 2024 | marketbeat.com2seventy bio (NASDAQ:TSVT) Given "Neutral" Rating at WedbushWedbush restated a "neutral" rating and issued a $5.00 price target on shares of 2seventy bio in a report on Monday.March 17, 2024 | marketwatch.comBristol Myers, 2seventy Bio's Cancer Treatment Wins FDA Committee ApprovalMarch 16, 2024 | msn.comBristol Myers wins FDA AdCom backing for Abecma label expansionMarch 15, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: 2seventy bio (TSVT), Immuneering (IMRX)March 15, 2024 | marketbeat.comTrading was temporarily halted for "TSVT" at 01:03 PM with a stated reason of "News pending."March 14, 2024 | marketwatch.com2seventy Bio Shares Fall on Concerns About FDA Panel's Meeting on Abecma Gene TherapyMarch 8, 2024 | marketbeat.comQ1 2024 EPS Estimates for 2seventy bio, Inc. Decreased by Wedbush (NASDAQ:TSVT)2seventy bio, Inc. (NASDAQ:TSVT - Free Report) - Investment analysts at Wedbush lowered their Q1 2024 earnings estimates for shares of 2seventy bio in a research note issued on Tuesday, March 5th. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($0.95) per share for the qMarch 7, 2024 | seekingalpha.com2Seventy Bio, Inc. (TSVT) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | msn.com2seventy bio, Inc. (NASDAQ:TSVT) Q4 2023 Earnings Call TranscriptMarch 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for 2seventy bio on FDA Meeting and Strong Financial OutlookMarch 7, 2024 | finance.yahoo.comDowngrade: Here's How Analysts See 2seventy bio, Inc. (NASDAQ:TSVT) Performing In The Near TermMarch 6, 2024 | finance.yahoo.comWhen Will 2seventy bio, Inc. (NASDAQ:TSVT) Turn A Profit?March 6, 2024 | marketbeat.com2seventy bio (NASDAQ:TSVT) Announces Earnings Results2seventy bio (NASDAQ:TSVT - Get Free Report) issued its quarterly earnings results on Tuesday. The company reported ($1.11) EPS for the quarter, topping the consensus estimate of ($1.22) by $0.11. 2seventy bio had a negative return on equity of 47.12% and a negative net margin of 126.06%. During the same quarter in the previous year, the business earned ($0.60) earnings per share.March 5, 2024 | investorplace.comTSVT Stock Earnings: 2seventy bio Misses EPS, Misses Revenue for Q4 2023March 5, 2024 | finance.yahoo.com2seventy bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational ProgressMarch 4, 2024 | benzinga.comA Preview Of 2seventy bio's EarningsMarch 1, 2024 | businesswire.com2seventy bio to Report Fourth Quarter and Full Year 2023 Financial Results and Participate in Upcoming Investor ConferencesFebruary 24, 2024 | msn.com2seventy bio (TSVT) Price Target Increased by 33.33% to 10.88February 18, 2024 | finance.yahoo.comTSVT Mar 2024 2.500 putFebruary 14, 2024 | marketbeat.com2seventy bio, Inc. (NASDAQ:TSVT) Given Consensus Rating of "Hold" by Brokerages2seventy bio, Inc. (NASDAQ:TSVT - Get Free Report) has received an average rating of "Hold" from the eight research firms that are covering the firm, Marketbeat reports. Five investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The avera Get 2seventy bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TSVT and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon Musk’s Next Move Will Disrupt AI Forever (Ad)A revolutionary venture that is set to get rolled out by May 16. One well-connected Silicon Valley VC has uncovered a way for anybody to claim a stake in "Elon Musk's AI 2.0" with as little as $100. Get all the information here. TSVT Media Mentions By Week TSVT Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TSVT News Sentiment▼0.040.57▲Average Medical News Sentiment TSVT News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TSVT Articles This Week▼152▲TSVT Articles Average Week Get 2seventy bio News Delivered to You Automatically Sign up to receive the latest news and ratings for TSVT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Immutep News Today Pyxis Oncology News Today Werewolf Therapeutics News Today Aldeyra Therapeutics News Today Design Therapeutics News Today 23andMe News Today Foghorn Therapeutics News Today Veru News Today Conduit Pharmaceuticals News Today AC Immune News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TSVT) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperDid Intel Just Dethrone Nvidia?Chaikin AnalyticsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAmerica’s worst nightmare?Porter & CompanyElon’s New Device is About to Shock the WorldInvestorPlaceClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 2seventy bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
